Continuing Treatment Not Beneficial After 5 Years of Bisphosphonates
No difference seen in cumulative incidence of hip fracture for continuing therapy for two, five additional years versus discontinuing
Bone Disorders
Most Users Report Cannabidiol Use for Treatment of Diagnosable Conditions
Psychiatric, orthopedic, and sleep issues most commonly cited in a Reddit forum
Vosoritide NDA for Achondroplasia Submitted for Review
Vosoritide is an investigational analogue of C-type natriuretic peptide.
Longer Bisphosphonate Drug Holiday May Up Fracture Risk
For those with previous vertebral fracture, major osteoporotic fractures increased with holidays >12 months.
Canakinumab Explored as Therapy for Large-Joint Osteoarthritis
Exploratory analysis reveals total hip/knee replacement rate reduced with canakinumab vs placebo.
Vertebral Fractures Up With Long-Term Delay of Denosumab
Increase in risk with long delay of subsequent doses not significant for composite of all fracture types
Contraceptives Beneficial for Premature Ovarian Insufficiency
Combined oral contraceptives linked to improvement in bone mass, similar to that with high-dose HT.
Crysvita Approved for Treatment of Tumor-Induced Osteomalacia
The FDA as approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
Proton Pump Inhibitors May Up Fracture Risk in Children
Small but significant risk seen for upper-limb and lower-limb fractures
Endocrine Society Updates Postmenopausal Osteoporosis Management Guidelines to Include Romosozumab
The Endocrine Society has issued an update to the organization’s 2019 clinical practice guideline on pharmacologic management of osteoporosis to include romosozumab.
